Variable	PRAL				NEAP			
	Tertile 1	Tertile 2	Tertile 3	P trend[b]	Tertile 1	Tertile 2	Tertile 3	P trend
Age (y)	55.77 ± 9.26	65.17 ± 9.03	66.12 ± 10.14	0.003	60.25 ± 9.12	65.05 ± 9.60	65.77 ± 10.01	0.01
BMI (kg/m2)	26.69 ± 3.46	24.37 ± 3.32	24.99 ± 3.61	0.03	26.53 ± 3.39	24.23 ± 3.45	25.28 ± 3.59	0.11
Energy intake (Kcal/day)	2827.76 ± 687.41	2521.78 ± 639.24	2612.98 ± 616.46	0.14	2765.64 ± 668.65	2674.07 ± 704.71	2522.82 ± 580.74	0.10
Ethnicity				0.71				0.95
Fars	31(77.5)	33(82.5)	30(75.0)		31(77.5)	32(80.0)	31(77.5)	
Non Fars	9(22.5)	7(17.5)	10(25.0)		9(22.5)	8(20.0)	9(22.5)	
job				0.96				0.52
Employment	24(60)	23(57.5)	24(60.0)		24(60.0)	21(52.5)	26(65.0)	
Unemployment **	16(40.0)	17(42.5)	16(40.0)		16(40.0)	19(47.5)	14(35.0)	
Education				0.07				0.04
Illiterate & primary	19(47.5)	25(62.5)	29(72.5)		19(47.5)	24(60.0)	30(75.0)	
Diploma & academic	21(52.5)	15(37.5)	11(27.5)		21(52.5)	16(40.0)	10(25.0)	
Smokers (%)	11(27.5)	12(30.0)	7(17.5)	0.39	11(27.5)	13(32.5)	6(15.0)	0.18
Physical activity				0.04				0.11
less or never	9(22.5)	11(27.5)	15(37.5)		9(22.5)	11(27.5)	15(37.5)	
moderate	12(30.0)	21(52.5)	16(40.0)		13(32.5)	20(50.0)	16(40.0)	
high	19(47.5)	8(20.0)	9(22.5)		18(45.0)	9(22.5)	9(22.5)	
Antihyperlipidemic drug user(%)	5(12.5)	2(5.0)	5(12.5)	0.44	5(12.5)	1(2.5)	6(15.0)	0.14
Antihypertensive drug user(%)	8(20.0)	9(22.5)	15(37.5)	0.16	9(22.5)	6(15.0)	17(42.5)	0.02
Aspirin user (%)	8(20.0)	11(27.5)	6(15.0)	0.38	9(22.5)	8(20.0)	8(20.0)	0.12

- PRAL, potential renal acid load; NEAP, net endogenous acid production; BMI, body mass index.
- ** Unemployed participants were retired or jobless individuals.
- [a] Data are presented as mean ± SD or number (percent).
- [b] P values are from one way analysis of variance (ANOVA) test for quantitative and Chi-square or Fischer exact tests for qualitative variables comparisons across tertiles of dietary acid load, respectively.

Table 1. General characteristics of participants across tertiles of PRAL and NEAP scores among 60 prostatic cancer cases and 60 hospital-based controls[a].

Table 2. Dietary intakes of participants across tertiles of PRAL and NEAP scores among 60 prostatic cancer cases and 60 hospital based controls[a].

Variables	PRAL				NEAP			
	Tertile 1 (N=40)	Tertile 2 (N=40)	Tertile 3 (N=40)	P-value[b]	Tertile 1 (N=40)	Tertile 2 (N=40)	Tertile 3 (N=40)	P-value
Carbohydrate (gr/day)	363.22 ± 13.87	316.94 ± 13.80	331.69 ± 13.71	0.06	362.87 ± 13.80	323.12 ± 13.74	325.86 ± 13.83	0.08
Protein (gr/day)	106.92 ± 3.07	104.56 ± 3.05	126.44 ± 3.03	<0.001	105.37 ± 3.08	106.66 ± 3.07	125.80 ± 3.09	<0.001
Total fat (gr/day)	60.12 ± 4.44	57.24 ± 4.42	68.30 ± 4.39	0.18	80.30 ± 4.35	54.88 ± 4.33	70.48 ± 4.36	0.04
Dietary fiber (gr/day)	27.96 ± 0.76	20.98 ± 0.75	18.96 ± 0.75	<0.001	27.67 ± 0.77	21.26 ± 0.77	18.98 ± 0.77	<0.001
Vitamin A (RAE/day)	3317.38 ± 206.04	2424.26 ± 205.01	3002.92 ± 203.70	0.01	3185.07 ± 207.16	2492.39 ± 206.17	3067.10 ± 207.56	0.04
Vitamin E (mg/day)	5.40 ± 0.20	4.05 ± 0.20	3.97 ± 0.20	<0.001	5.39 ± 0.20	4.09 ± 0.20	3.94 ± 0.20	<0.001
Vitamin K (µg/day)	152.70 ± 7.70	109.27 ± 7.66	109.83 ± 7.62	<0.001	150.75 ± 7.72	113.12 ± 7.68	107.93 ± 7.73	<0.001
Vitamin D (µg/day)	1.74 ± 0.37	1.56 ± 0.36	1.48 ± 0.36	0.88	1.75 ± 0.36	1.21 ± 0.36	1.83 ± 0.36	0.43
Vitamin C (mg/day)	221.67 ± 8.05	163.70 ± 8.01	135.23 ± 7.96	<0.001	220.62 ± 8.09	163.31 ± 8.05	136.67 ± 8.10	<0.001
Vitamin B1 (mg/day)	2.46 ± 0.08	2.29 ± 0.08	2.41 ± 0.08	0.29	2.45 ± 0.08	2.33 ± 0.08	2.38 ± 0.08	0.56
Vitamin B2 (mg/day)	2.32 ± 0.14	2.18 ± 0.14	2.74 ± 0.14	0.02	2.30 ± 0.14	2.24 ± 0.14	2.71 ± 0.14	0.05
Vitamin B3 (mg/day)	28.35 ± 1.10	28.66 ± 1.09	33.11 ± 1.08	0.003	28.14 ± 1.08	28.76 ± 1.08	33.23 ± 1.09	0.002
Vitamin B5 (mg/day)	7.06 ± 0.24	6.39 ± 0.24	7.17 ± 0.24	0.05	7.02 ± 0.24	6.50 ± 0.24	7.11 ± 0.24	0.15
Vitamin B6 (mg/day)	2.95 ± 0.18	2.27 ± 0.17	2.33 ± 0.17	0.01	2.93 ± 0.18	2.28 ± 0.17	2.34 ± 0.18	0.02
Vitamin B9 (µg/day)	401.88 ± 12.27	316.47 ± 12.21	317.08 ± 12.13	<0.001	397.63 ± 12.39	321.68 ± 12.32	316.12 ± 12.41	<0.001
Vitamin B12 (µg/day)	7.49 ± 2.60	8.75 ± 2.59	20.38 ± 2.57	0.001	6.85 ± 2.59	9.44 ± 2.57	20.32 ± 2.59	0.001
Potassium (mg/day)	5544.70 ± 154.99	4094.10 ± 154.21	3888.35 ± 153.23	<0.001	5493.94 ± 156.91	4160.38 ± 156.16	3865.63 ± 157.21	<0.001
Calcium (mg/day)	1280.50 ± 36.32	1051.64 ± 36.14	1063.23 ± 35.91	<0.001	1277.21 ± 36.06	1097.82 ± 35.89	1050.34 ± 36.13	<0.001
Iron (mg/day)	24.38 ± 1.51	22.67 ± 1.50	27.57 ± 1.49	0.06	23.69 ± 1.50	23.32 ± 1.49	27.61 ± 1.50	0.09
Magnesium (mg/day)	454.75 ± 12.46	358.39 ± 12.40	341.26 ± 12.32	<0.001	448.73 ± 12.71	364.13 ± 12.65	341.54 ± 12.74	<0.001
Zinc (mg/day)	11.81 ± 0.37	11.03 ± 0.37	12.63 ± 0.37	0.01	11.61 ± 0.37	11.16 ± 0.37	12.70 ± 0.37	0.01
Phosphorous (mg/day)	1511.73 ± 38.08	1379.47 ± 37.88	1476.19 ± 37.64	0.04	1502.47 ± 38.36	1410.48 ± 38.18	1454.43 ± 38.43	0.24
Fruits (gr/day)	637.78 ± 35.03	468.35 ± 34.39	345.34 ± 34.16	<0.001	639.18 ± 35.02	455.65 ± 34.39	356.67 ± 34.63	<0.001
Vegetables (gr/day)	812.68 ± 31.04	604.28 ± 30.89	548.17 ± 30.69	<0.001	800.50 ± 31.50	612.12 ± 31.35	552.51 ± 31.56	<0.001
Dairy (gr/day)	441.27 ± 25.33	400.38 ± 35.20	378.46 ± 25.04	0.21	451.44 ± 24.84	404.57 ± 24.72	364.10 ± 24.89	0.05
Nut/Legumes (gr/day)	56.34 ± 2.69	55.69 ± 2.68	51.57 ± 2.66	0.39	54.67 ± 2.65	58.23 ± 2.64	50.70 ± 2.66	0.14
Grains (gr/day)	367.97 ± 13.78	414.07 ± 13.71	429.46 ± 13.63	0.01	371.38 ± 13.81	416.23 ± 13.75	423.88 ± 13.84	0.02
Fish/Poultry (gr/day)	91.08 ± 7.51	99.50 ± 7.47	131.66 ± 7.43	<0.001	89.86 ± 7.57	104.48 ± 7.53	127.90 ± 7.58	0.002
Red/processed meats (gr/day)	65.38 ± 7.60	74.59 ± 7.56	112.80 ± 7.51	<0.001	61.30 ± 7.33	74.79 ± 7.29	116.67 ± 7.34	<0.001

- PRAL, potential renal acid load; NEAP, net endogenous acid production.
- [a] Data are presented as mean ± SE.
- [b] Ancova test was used.

Table 3. Risk of prostate cancer in relation to PRAL and NEAP among 60 prostatic cancer cases and 60 hospital-based controls[a].

Patterns	Categories of PRAL and NEAP scores			
	Tertile 1	Tertile 2	Tertile 3	P trend
PRAL	(<-14.28 mEq/d)	(-14.28 to 2.57 mEq/d)	(> 2.57 mEq/d)	
No. cases/controls	12/28	20/20	28/12	
Crude	1.00 (Ref)	2.33(0.93-5.84)	4.88(2.22-13.41)	0.001
Model 1	1.00 (Ref)	1.78(0.62-5.12)	3.94(1.37-1131)	0.01
Model 2	1.00 (Ref)	1.72(0.89-5.04)	3.94(1.32-11.71)	0.01
Model 3	1.00 (Ref)	2.07(0.68-6.32)	3.42(1.11-8.65)	0.03
NEAP	(<38.09 mEq/d)	(38.09 to 49.97 mEq/d)	(> 49.97 mEq/d)	
No. cases/controls	12/28	20/20	28/12	
Crude	1.00 (Ref)	2.33(0.93-5.84)	5.44(2.09-14.17)	0.001
Model 1	1.00 (Ref)	1.64(0.59-4.58)	4.25(1.49-12.10)	0.01
Model 2	1.00 (Ref)	1.55(0.55-4.39)	4.29(1.45-12.71)	0.01
Model 3	1.00 (Ref)	1.63(0.56-4.79)	3.88(1.26-9.55)	0.02

- PRAL, potential renal acid load; NEAP, net endogenous acid production.
- [a] Multivariate logistic regression was used.
- Data are presented as odds ratio (95% confidence interval).
- Model 1: Adjusted for age, body mass index, energy intake, smoking, and physical activity.
- Model 2: Adjusted for confounders in model 1 plus ethnicity, job, and education.
- Model 3: Adjusted for confounders in model 2 plus drug usage (Antihyperlipidemic drugs, antihypertensive drugs, and aspirin).